Vir Biotechnology, Inc. Restricted Cash and Cash Equivalents
Vir Biotechnology, Inc. (VIR) had Restricted Cash and Cash Equivalents of $8.90 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-08-05
- 2026-06-30: Restricted Cash and Cash Equivalents $8.90M.
- 2026-03-31: Restricted Cash and Cash Equivalents $8.90M.
- 2025-09-30: Restricted Cash and Cash Equivalents $9.20M.
- 2025-06-30: Restricted Cash and Cash Equivalents $95.20M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $8.90M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $8.90M 10-Q · filed 2026-05-07 |
| 2025-09-30 | $9.20M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $95.20M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $94.40M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $95.70M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |